Skip to content
PodParley
GRACEcast podcast artwork

PODCAST · health

GRACEcast

by cancerGRACE Meetings

Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit CancerGRACE.org for more info.

Publisher-supplied feed metadata · PodParley refreshed Aug 17, 2026 · Source feed

Subscribe · 0 Bookmark

Episodes

  1. FCR vs. BR - Is One Better?

    Jennifer Brown, MD, discusses the choice in chemoimmunotherapy, FCR (fludarabine, cyclophosphamide and rituximab) vs BR. FCR has been the standard therapy for previously untreated fit patients with CLL under about the age of 70. While BR (bendamustine and rituximab), is a relatively newer…

    more

  2. Basics of Small Cell Lung Cancer

    Lung Cancer Video Library ASCO 2016 Rachel Sanborn Basics of Small Cell Lung Cancer

  3. Adjuvant Chemotherapy for Elderly and Frail Patients

    Lung Cancer Video Library ASCO 2016 - Rachel Sanborn - Adjuvant Chemotherapy for Elderly and Frail Patients

  4. Rachel Sanborn - Adjuvant Chemotherapy for Early Stage NSCLC Patients, part 1

    Lung Cancer Video Library - Rachel Sanborn - Adjuvant Chemotherapy for Early Stage NSCLC Patients, part 1

  5. New Trials of Targeting Therapies to Treat Leptomeningeal Carcinomatosis

    GRACE is happy to present the 8th in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer. Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and...

  6. ASCO 2016 LC RT Vid 8 - Promising Early Results for Treatments

    GRACE is happy to present the 8th in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer. Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and...

  7. Immuno-oncology Developments - Combinations and Use as First-Line Therapy

    GRACE is happy to present the 6th in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer. Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and...

  8. Does Current Evidence Support Favoring Proton-Beam Radiation

    GRACE is happy to present the 6th video in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer. Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the…

    more

  9. J-Alex Trial: Should Alecensa Replace Xalkori as First-Line ALK Therapy?

    GRACE is happy to present the 5th in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer. Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and...

  10. Are There Less Toxic Alternatives to the Extreme Regimen

    GRACE is happy to present the 9th video in our series ASCO 2016 Head and Neck Roundtable, Treating Head and Neck Cancer. Featuring Jared Weiss, MD, Joshua Bauml, MD, and Tanguy Seiwert, MD, this roundtable discussion, moderated by Dr. Weiss, highlights intriguing discussions regarding head and…

    more

  11. Promising Early Data for Oral Inhibitor Buparlisib

    GRACE is happy to present the 8th video in our series ASCO 2016 Head and Neck Roundtable, Treating Head and Neck Cancer. Featuring Jared Weiss, MD, Joshua Bauml, MD, and Tanguy Seiwert, MD, this roundtable discussion, moderated by Dr. Weiss, highlights intriguing discussions regarding head and…

    more

  12. Using Immunotherapy as First-Line Treatment and in Combinations

    7th video in our series ASCO 2016 Head and Neck Roundtable, featuring Jared Weiss, MD, Joshua Bauml, MD, and Tanguy Seiwert, MD. Dr. Weiss moderates the discussion regarding ASCO 2016 HN RT-Using Immunotherapy as First-Line Treatment and in Combinations.

  13. Keynote 55 Pembrolizumab for Heavily Pre-Treated Patients

    6th video in our series ASCO 2016 Head and Neck Roundtable, featuring Jared Weiss, MD, Joshua Bauml, MD, and Tanguy Seiwert, MD. Dr. Weiss moderates the discussion regarding keynote 55: Pembrolizumab for heavily pre-treated patients.

  14. Using Biomarkers in Immunotherapy

    GRACE is happy to present the 3rd video in our series ASCO 2016 Head and Neck Roundtable, Treating Head and Neck Cancer. Featuring Jared Weiss, MD, Joshua Bauml, MD, and Tanguy Seiwert, MD, this roundtable discussion, moderated by Dr. Weiss, highlights intriguing discussions regarding head and…

    more

  15. Common Side Effects of PD-1 Inhibitors

    GRACE is happy to present the 4th video in our series ASCO 2016 Head and Neck Roundtable, Treating Head and Neck Cancer. Featuring Jared Weiss, MD, Joshua Baumi, MD, and Tanguy Seiwert, MD, this roundtable discussion, moderated by Dr. Weiss, highlights intriguing discussions regarding head and…

    more

  16. Data from Keynote 12 Nivolumab and Pembrolizumab

    GRACE is happy to present the 3rd video in our series ASCO 2016 Head and Neck Roundtable, Treating Head and Neck Cancer. Featuring Jared Weiss, MD, Joshua Baumi, MD, and Tanguy Seiwert, MD, this roundtable discussion, moderated by Dr. Weiss, highlights intriguing discussions regarding head and…

    more

  17. How Promising Are The Results From Checkmate 141?

    GRACE is happy to present the 2nd video in our series, ASCO 2016 Head and Neck Roundtable, Treating Head and Neck Cancer. Featuring Jared Weiss, MD, Joshua Baumi, MD, and Tanguy Seiwert, MD, this roundtable discussion, moderated by Dr. Weiss, highlights intriguing discussions regarding head and...

  18. Local Consolidation Therapies for Oligomatastases

    GRACE is happy to present the 4th in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer. Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and...

  19. The Immune System and PD-1 Inhibitors

    GRACE is happy to present the 1st video in our series ASCO 2016 Head and Neck Roundtable, Treating Head and Neck Cancer. Featuring Jared Weiss, MD, Joshua Baumi, MD, and Tanguy Seiwert, MD, this roundtable discussion, moderated by Dr. Weiss, highlights intriguing discussions regarding head and…

    more

  20. Urine or Blood Testing Instead of Lung Biopsy Shows Promise for Finding EGFR Mutations

    GRACE is happy to present our ASCO 2016 Lung Cancer Roundtable series, Highlights and New Approaches in Lung Cancer. Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most...

  21. Can Online Patient Groups Speed New Targeted Therapies?

    GRACE is happy to present our ASCO 2016 Lung Cancer Roundtable series, Highlights and New Approaches in Lung Cancer. Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most...

  22. Rova-T Shows Promise in Small Cell Lung Cancer

    1st Video in the GRACE ASCO 2016 Lung Cancer Roundtable series, featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD. Dr. West moderates this roundtable discussion highlighting studies presented at ASCO 2016. For this video, Rova-T is presented as showing...

  23. Significance Of IGHV Mutations & How They Are Assessed

    CLL, Chronic Lymphocytic Leukemia, What is the significance of IGHV mutations and how they are assessed. Presented by Jennifer Brown, M.D., Ph.D., Director of the CLL Center and the Dana-Farber Cancer Institute.

  24. Immunotherapy Combinations

    Dr. Jack West, Swedish Cancer Institute, discusses current trials seeking to determine the efficacy of combining immunotherapy agents in lung cancer.

  25. Immunotherapy as First-Line Treatment

    Dr. Jack West, Swedish Cancer Institute, raises the question of whether to use immune checkpoint inhibitors as first-line treatment of lung cancer, alone or in combination with chemotherapy.

  26. Lung Cancer Screening - Process and Potential Benefits

    Dr. Jed Gorden, Swedish Cancer Institute, reviews the lung cancer screening process, including low-dose CT scanning, smoking cessation, follow-up testing and counseling, and describes the potential benefits.

  27. Bronchoscopy and EBUS

    Dr. Jed Gorden, Swedish Cancer Institute, describes the differences between bronchoscopy and endobronchial ultrasound, highlighting the advantages of EBUS in diagnosis and staging.

  28. Maintenance Therapy for Advanced NSCLC

    Dr. Jack West, Swedish Cancer Institute, defines maintenance therapy in advanced NSCLC and discusses maintenance treatment strategies.

  29. Rociletinib/Osimertinib for EGFR T790M-negative NSCLC

    Dr. Jack West, Swedish Cancer Institute, reviews trial evidence for the efficacy of rociletinib and osimertinib for EGFR acquired resistance not driven by a T790M mutation.

  30. Are There Clinically Significant Distinctions Between PD-1 and PD-L1?

    Dr. Jack West, Swedish Cancer Institute, compares the mechanism of action, efficacy and toxicity of PD-1 and PD-L1 inhibitors.

  31. Histology-Specific Recommendations - Large-Cell Neuroendocrine

    Dr. Jack West, Swedish Cancer Institute, identifies the best choice for first-line chemotherapy for large-cell neuroendocrine histology.

  32. Histology-Specific Regimens - Squamous

    Dr. Jack West, Swedish Cancer Institute, reviews the choices for a first-line chemotherapy regimen based on a squamous histology.

  33. Histology-Specific Regimens - Adenocarcinoma

    Dr. Jack West, Swedish Cancer Institute, addresses the issue of choosing a first-line chemotherapy regimen based on an adenocarcinoma histology.

  34. What is the Role of Bevacizumab in Stage IV NSCLC?

    Dr. Jack West, Swedish Cancer Institute, discusses the anti-angiogenic agent bevacizumab (Avastin) and the trial evidence of its efficacy for non-squamous NSCLC.

  35. Platinum-Based Chemo Doublets: Backbone for NSCLC Treatment

    Dr. Jack West, Swedish Cancer Institute, identifies the platinum-based chemotherapy doublet as the backbone of first-line treatment for the majority of NSCLC patients.

  36. Timing of Second Generation ALK Inhibitors: First Line vs. Treatment after Acquired Resistance

    Dr. Ross Camidge, University of Colorado, addresses the question of whether to use a second generation ALK inhibitor as first line therapy or only after acquired resistance to crizotinib.

  37. CNS Disease in ALK-Positive NSCLC: Monitoring and Systemic vs. Radiation Therapy

    Dr. Ross Camidge, University of Colorado, discusses management of CNS progression for ALK-positive NSCLC including monitoring frequency and preferences between systemic and radiation therapy.

  38. Ceritinib and Other Second Generation ALK Inhibitors for Acquired Resistance in ALK-Positive NSCLC

    Dr. Ross Camidge, University of Colorado, describes the second generation ALK-inhibitors which provide good options for ALK-positive NSCLC patients who have developed acquired resistance to crizotinib.

  39. Crizotinib for First Line Treatment of ALK or ROS1 Rearrangements

    Dr. Ross Camidge, University of Colorado, explains the preference for crizotinib rather than platinum doublet chemotherapy as first line treatment for patients with ALK or ROS1 rearrangements.

  40. ROS-1 Rearrangements: What Are They?

    Dr. Ross Camidge, University of Colorado, describes ROS-1 rearrangements and compares them to ALK rearrangements in frequency of occurrence and response to treatment.

  41. ALK Rearrangements: What Are They, and Who Has Them?

    Dr. Ross Camidge, University of Colorado, describes ALK rearrangements and the characteristics of patients who most often have them.

  42. Multiplex Testing for Rare Mutations: What Are the Potential Benefits?

    Dr. Ross Camidge, University of Colorado, discusses the potential benefits as well as the disadvantages of multiplex mutation testing.

  43. The Role of Targeted Therapy Post-Resection

    Dr. Heather Wakelee, Stanford University Medical Center, evaluates the lack of evidence for the use of targeted therapies after surgery, and describes ongoing trials attempting to resolve that issue.

  44. What Is a Standard Adjuvant Chemotherapy Regimen?

    Dr. Heather Wakelee, Stanford University Medical Center, lists standard adjuvant chemotherapy regimens, comparing their administration and uses.

  45. Why Give Adjuvant Chemotherapy, and to Which Patients?

    Dr. Heather Wakelee, Stanford University Medical Center, discusses the purpose of adjuvant chemotherapy, and which patients benefit most from it.

  46. Zoledronate or Denosumab for Lung Cancer with Bone Metastases

    Dr. Benjamin Levy, Mount Sinai Health Systems, compares zoledronic acid and denosumab, two agents used for treatment of bone metastases in lung cancer.

  47. How Rate of Progression Can Affect Treatment Decisions

  48. Platinum-Based Doublets As the Cornerstone of First Line Treatment

    Dr. Benjamin Levy, Mount Sinai Health Systems, discusses platinum-based chemotherapy as the standard of care for advanced NSCLC patients without targetable genetic mutations.

  49. What are the Goals of Treating Advanced NSCLC?

    Dr. Benjamin Levy, Mount Sinai Health Systems, lists the goals of treating advanced NSCLC and the methods used to achieve those goals.

  50. Video-Assisted Thorascopic Surgery vs. Open Thoracotomy

    Dr. David Harpole, Duke University Medical Center, compares traditional open thoracotomy with video-assisted thorascopic surgery, highlighting the advantages of the newer approach.

View all 599 episodes →

Type above to search every episode's transcript for a word or phrase. Matches are scoped to this podcast.

Searching…

We're indexing this podcast's transcripts for the first time — this can take a minute or two. We'll show results as soon as they're ready.

No matches for "" in this podcast's transcripts.

Showing of matches

No topics indexed yet for this podcast.

Loading reviews...

ABOUT THIS SHOW

Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit CancerGRACE.org for more info.

HOSTED BY

cancerGRACE Meetings

Frequently Asked Questions

How many episodes does GRACEcast have?

GRACEcast currently has 599 episodes available on PodParley. New episodes are automatically indexed when they're published to the podcast feed.

What is GRACEcast about?

Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to...

How often does GRACEcast release new episodes?

GRACEcast releases new episodes frequently with a large back catalog of 599 episodes. Check the episode list for recent publication dates.

Where can I listen to GRACEcast?

You can listen to GRACEcast on PodParley by clicking any episode. We provide an embedded audio player for direct listening, and you can also subscribe via your preferred podcast app using the RSS feed.

Who hosts GRACEcast?

GRACEcast is created and hosted by cancerGRACE Meetings.
URL copied to clipboard!